Fosun Pharma
A Chinese pharmaceutical and healthcare group active in drug development, manufacturing, medical devices, diagnostics, and healthcare services.
Last updated November 4, 2026
AI crawler reads
4requests
1companies- Anthropic4
- Profile
- 2
- Controversies
- 2
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Fosun Pharma is the pharmaceutical and healthcare platform associated with Fosun International. Its predecessor, Shanghai Fortune Industrial Company, was established in January 1994, while the listed company was incorporated and launched its A-share initial public offering in the late 1990s. The business subsequently adopted the Fosun name in English and shifted its corporate identity from a general industrial company toward pharmaceuticals and healthcare. It later expanded its capital-market presence through a Hong Kong listing in 2012. The company operates across several connected areas. Its core activities include pharmaceutical research, development, production, licensing, commercialization, and distribution. It also has interests in medical devices, in-vitro diagnostics, healthcare services, and international healthcare businesses. This diversified structure allows Fosun Pharma to combine manufacturing and commercial infrastructure with investments and partnerships in specialized products, biologics, medical technology, and overseas distribution. A significant early strategic move was Fosun Pharma's investment in Sinopharm-related assets. In 2003 it acquired a 49% interest in Sinopharm Group, later holding an interest in Sinopharm Industrial Investment before Sinopharm Group's public-market development. The company then broadened its international exposure through transactions and partnerships. In 2014 it participated in a consortium that acquired US-listed Chindex International, whose businesses included private hospitals in mainland China. In 2016 it agreed to acquire approximately 74% of India's Gland Pharma, completing the transaction in 2017 after regulatory review. Gland Pharma strengthened Fosun Pharma's position in injectable and generic medicines and gave the group a substantial Indian operating platform. Fosun Pharma has also developed and separated specialized businesses. Sisram Medical, the parent of Alma Lasers, was spun off and listed in Hong Kong in 2017; Fosun Pharma retained a majority holding at the end of that year. The group also acquired Tridem Pharma in 2017 through subsidiaries. The French company was focused on pharmaceutical distribution in African markets, supporting Fosun Pharma's stated internationalization strategy. In 2021 Fosun Pharma entered a partnership with Insilico Medicine intended to facilitate that company's entry into the Chinese market. During the COVID-19 pandemic, Fosun Pharma developed a nucleic-acid detection kit and obtained regulatory or market clearances described in public materials, including emergency authorization in the United States, approval in China, and European CE certification. The company also supplied protective and medical equipment to epidemic-control areas. Its most prominent pandemic partnership was with BioNTech. In March 2020, Fosun invested in BioNTech and obtained development and commercialization rights for the company's mRNA COVID-19 vaccine in mainland China, while later partnering with Jacobson Pharma for supply to Hong Kong and Macau. Fosun initially conducted Chinese testing of BNT162b1, then discontinued further development of that candidate in favor of BNT162b2 after comparative data indicated a more favorable safety profile for the latter. The partnership made Fosun a central Chinese commercialization participant for the BioNTech vaccine, although the timing and regulatory pathway for mainland availability remained subject to Chinese approval. Fosun Pharma is listed in mainland China and Hong Kong and has been included in major Chinese equity indexes. Its business combines domestic pharmaceutical scale with international subsidiaries, equity investments, licensing arrangements, and distribution networks. Publicly identified senior figures include Wu Yifang, president and chief executive officer, and Chen Qiyu, chairman of Fosun Pharma and co-chief executive officer of Fosun International. The company remains an active Fosun Group healthcar…
History
Fosun Pharma traces its origins to Shanghai Fortune Industrial Company, established in January 1994. Its early shareholders included Fosun High Technology and its parent, Guangxin Technology, which was associated with Fosun's founding entrepreneurs. The listed corporate entity was established in 1998 and initially used the English name Shanghai Fortune Industrial Joint-Stock Co., Ltd. The company later changed the transliteration of its Chinese name from Fortune to Fosun and replaced the broader Industrial designation with Pharmaceutical, reflecting the development of its principal business identity. The company began trading A shares in 1998 and later listed H shares in Hong Kong in 2012. Fosun High Technology, an intermediate holding company within the Fosun structure, was connected to Fosun International, which became publicly listed in 2007. Fosun Pharma's relationship with the wider group has generally given it access to capital, investment resources, and healthcare-related businesses while leaving Fosun Pharma as a separately listed operating platform. Fosun Pharma expanded beyond its original pharmaceutical base through investments in distribution, healthcare services, medical technology, and international manufacturing. In 2003 it acquired a 49% stake in Sinopharm Group and later held the direct parent investment vehicle, Sinopharm Industrial Investment, before Sinopharm's public-market development. In 2014 it joined a consortium involved in the acquisition of Chindex International, a business associated with private hospitals in mainland China. International expansion accelerated in the second half of the 2010s. Fosun Pharma agreed in 2016 to acquire roughly 74% of Gland Pharma in India. The deal required regulatory engagement and was completed in October 2017. Gland added an important Indian pharmaceutical platform, particularly in injectable and generic medicines. In the same period, Sisram Medical, whose activities included the Alma Lasers medical-aesthetics business, was separated and listed in Hong Kong. Fosun Pharma retained a majority stake reported at 52.83% at the end of 2017. Fosun subsidiaries also acquired Tridem Pharma, a French distributor with an Africa-focused commercial footprint. The COVID-19 period demonstrated the company's reliance on both internal capabilities and external partnerships. Fosun Pharma developed a PCR-based nucleic-acid diagnostic kit and reported obtaining relevant Chinese, US, and European certifications or authorizations. It also donated masks, protective clothing, ventilators, ambulances, and other supplies to affected areas. In March 2020, Fosun invested in BioNTech and obtained rights relating to the development and commercialization of the BNT162b2 mRNA vaccine in mainland China. Fosun initially tested BNT162b1 in China, but announced in November 2020 that it would stop further trials of that candidate after BNT162b2 demonstrated a more favorable safety profile in broader testing. It subsequently pursued a regulatory pathway for BNT162b2 and arranged a supply partnership for Hong Kong and Macau. In 2021 Fosun Pharma partnered with Insilico Medicine to help the company enter the Chinese market. Across its history, Fosun Pharma has therefore evolved from a Shanghai-based listed industrial enterprise into a diversified pharmaceutical and healthcare group. Its current model combines drug research and manufacturing with biologics, diagnostics, devices, healthcare services, international subsidiaries, licensing, and strategic investments.
- 2021
Insilico Medicine partnership
[1]Fosun Pharma partnered with Insilico Medicine to facilitate its entry into the Chinese market.
- 2020
BioNTech COVID-19 vaccine collaboration
[1]Fosun invested in BioNTech and obtained China-related rights for the company's mRNA COVID-19 vaccine program.
- 2017
Gland Pharma transaction completed
[1]The acquisition of approximately 74% of Gland Pharma was completed in October.
- 2017
Sisram Medical spin-off
[1]Sisram Medical was separated and listed on the Hong Kong Stock Exchange.
- 2017
Tridem Pharma acquisition
[1]Fosun subsidiaries acquired the Africa-focused French drug distributor Tridem Pharma.
- 2016
Agreement to acquire Gland Pharma
[1]Fosun Pharma agreed to acquire approximately 74% of India's Gland Pharma, subject to regulatory processes.
- 2012
Hong Kong listing
[1]Fosun Pharma completed its H-share listing in Hong Kong.
- 2003
Sinopharm investment
[1]Fosun Pharma acquired a 49% stake in Sinopharm Group.
- 1998
A-share listing
[1]The listed company was incorporated under its earlier English identity and began its A-share initial public offering.
- 1994
Predecessor established
[1]Shanghai Fortune Industrial Company, the predecessor of Fosun Pharma, was incorporated in January.
Products and positioning
An innovation-oriented and increasingly international Chinese pharmaceutical and healthcare group combining in-house development, manufacturing, commercialization, strategic investment, and partnerships.
Antimalarial medicines
Artesunate-based antimalarial products
Fosun Pharma has been associated with the development and commercialization of artesunate-based antimalarial medicines. These products represent the company's longstanding pharmaceutical manufacturing and international public-health orientation, particularly in markets where malaria treatment is a major healthcare need.
Biosimilar medicine
Han Li Kang
Han Li Kang is Fosun Pharma's rituximab biosimilar and is part of the company's biologics portfolio. It illustrates Fosun's strategy of combining domestic development and manufacturing with broader access to established biologic therapies.
Cell therapy
Fosun Kite CAR-T therapies
Fosun Kite is the cell-therapy platform associated with Fosun Pharma's CAR-T activities. The platform reflects the group's move into advanced oncology treatments and its use of international partnerships to develop and commercialize innovative therapies.
Vaccine · 2020
BioNTech mRNA COVID-19 vaccine program
Through its agreement with BioNTech, Fosun Pharma obtained development and commercialization rights for the mRNA COVID-19 vaccine program in mainland China and pursued related regulatory and supply activities. The arrangement made Fosun a regional partner rather than the global developer of the vaccine.
In-vitro diagnostics · 2020
PCR nucleic-acid detection kit
During the COVID-19 pandemic, Fosun Pharma developed a 2019-nCoV nucleic-acid detection kit based on PCR technology. Public reference material states that the product received Chinese approval, US emergency authorization, and European CE certification as an in-vitro diagnostic reagent.
Controversies
2022
La Jolla Pharmaceutical sues over Giapreza patents
La Jolla Pharmaceutical Company, La Jolla Pharma, LLC, and George Washington University filed a case against Gland Pharma Limited, Shanghai Fosun Pharmaceutical Group Co LTD, and Fosun Pharma USA Inc., alleging patent violations related to Giapreza.
2021
BioNTech vaccine batch paused in Hong Kong and Macau after vial-cap defect
BioNTech notified Fosun Pharma of a vial-cap defect in BNT162b2 batch 210102 supplied to Hong Kong and Macau. BioNTech and Fosun Pharma began investigating the cause, and the batch was paused for vaccination until the investigation ends; Fosun Pharma also said batch 210104 intended for Hong Kong would be stored and not sent to vaccination sites pending further notice.
2020
Ministry of Finance's Major Pharma Audit: Subsidiary Fined Over Promotion Fee Invoices
At the end of 2020, the Ministry of Finance announced the results of accounting information quality inspections in the pharmaceutical industry; Fosun Pharma subsidiary Jiangsu Wanbang and others were penalized (fined 50,000 yuan) for issues including using false invoices to expense promotion fees, while China Resources, Buchang and other drugmakers were also named. Media questioned whether false invoicing concealed commercial bribery funds. Fined and ordered to rectify.
2020
Pfizer responds to controversy over China’s exclusion from vaccine collaboration
In March 2020, Pfizer addressed controversy over the exclusion of China from its COVID-19 vaccine collaboration with BioNTech. Pfizer stated that the collaboration did not include China because BioNTech had already partnered with Fosun Pharma for the Chinese market. Pfizer said it was working to resolve details and was committed to access to medicines and vaccines for patients in China and globally.
2018
Subsidiary Has Drug GMP Certificate Revoked for Violations
In 2018, Chongqing Pharmaceutical Industry Research Institute, a controlled subsidiary of Fosun Pharma, violated drug GMP rules because it changed the production process for aripiprazole API without filing as required; the Chongqing drug regulator warned it, revoked its GMP certificate and ordered rectification. The investigation said the three related products were quality-qualified; the incident occurred during a period of tighter drug regulation after the Changchun Changsheng vaccine scandal.
Marketing campaigns
- 2020COVID-19 response and medical-supply donations
China
Fosun Pharma supported epidemic-control efforts by developing a PCR diagnostic kit and donating masks, protective clothing, ventilators, negative-pressure ambulances, and other medical supplies to affected areas. The reported value of donated supplies exceeded RMB 30 million by August 2020.
Outcome. Expanded the company's public-health role during the pandemic and supported diagnostic and emergency-response capacity.
- 2020BioNTech vaccine development and commercialization partnership
Mainland China · Hong Kong · Macau
Fosun Pharma invested in BioNTech and obtained China-related rights for its COVID-19 mRNA vaccine program. It initially tested BNT162b1, later shifted its focus to BNT162b2, and agreed with Jacobson Pharma to supply doses to Hong Kong and Macau.
Outcome. Established Fosun as BioNTech's China partner for the vaccine program, although mainland commercialization remained dependent on Chinese regulatory approval.
Brand decisions
2020
Invest in BioNTech and secure China vaccine rightsOtherBackground
Fosun Pharma sought access to an mRNA COVID-19 vaccine during the early global pandemic.
Action taken
Fosun invested US$135 million in BioNTech in exchange for approximately 1.58 million BioNTech shares and future development and marketing rights for the vaccine in China.
Aftermath
Fosun became BioNTech's China partner and redirected its Chinese clinical and regulatory strategy from BNT162b1 toward BNT162b2.
Strategic investment. US$135 million (17 March 2020)
2020
Shift from BNT162b1 to BNT162b2Generation changeBackground
Early clinical testing in China had focused on BNT162b1, while broader trials indicated that BNT162b2 had a more favorable safety profile.
Action taken
Fosun stopped further trials of BNT162b1 and concentrated on seeking Chinese approval for BNT162b2.
Aftermath
The company's vaccine strategy moved toward a bridge-study and regulatory approach based on the larger international BNT162b2 evidence base.
2017
Acquire Tridem PharmaM&ABackground
Fosun Pharma pursued international distribution capabilities, with particular interest in African pharmaceutical markets.
Action taken
Fosun subsidiaries Fosun Pharma A.G. and Fosun Industrial acquired the French distributor Tridem Pharma.
Aftermath
The transaction added an Africa-focused distribution business to Fosun Pharma's international network.
Maximum stated consideration. Up to EUR 63 million (2017)
2016
Acquire approximately 74% of Gland PharmaM&ABackground
Fosun Pharma sought an international manufacturing and commercial platform in India, particularly in injectable and generic medicines.
Action taken
It agreed to acquire approximately 74% of Gland Pharma, with the transaction subject to regulatory review and later completion.
Aftermath
The acquisition was completed in October 2017 and became one of Fosun Pharma's most significant overseas transactions.
Maximum stated consideration. Up to US$1,091.30 million, including up to US$25 million in contingent consideration linked to US enoxaparin sales (2016 agreement; completed October 2017)
Recent events
Reported
La Jolla Pharmaceutical sues over Giapreza patents[10]
La Jolla Pharmaceutical Company, La Jolla Pharma, LLC, and George Washington University filed a case against Gland Pharma Limited, Shanghai Fosun Pharmaceutical Group Co LTD, and Fosun Pharma USA Inc., alleging patent violations related to Giapreza.
Fosun Pharma and Insilico Medicine announce AI drug-discovery partnership[12]
Fosun Pharma and Insilico Medicine announced a global strategic partnership to advance AI-driven drug research across multiple targets, including development work on Insilico Medicine’s QPCTL project. The agreement includes a $13 million upfront payment to Insilico Medicine, milestone payments, profit sharing for the QPCTL project, and an equity investment by Fosun Pharma.
Reported
Fosun Industrial signs Taiwan vaccine sales agreement[13]
Fosun Industrial signed an agreement to sell a total of 10 million doses of the mRNA COVID-19 vaccine to TSMC, Hon Hai and the Yongling Foundation for supply to Taiwan.
BioNTech vaccine batch paused in Hong Kong and Macau after vial-cap defect[11]
BioNTech notified Fosun Pharma of a vial-cap defect in BNT162b2 batch 210102 supplied to Hong Kong and Macau. BioNTech and Fosun Pharma began investigating the cause, and the batch was paused for vaccination until the investigation ends; Fosun Pharma also said batch 210104 intended for Hong Kong would be stored and not sent to vaccination sites pending further notice.
Reported
Fosun Pharma appoints Wu Yifang chairman and CEO[14]
Fosun Pharma announced that Wu Yifang would serve as its executive director, chairman and CEO, succeeding Chen Qiyu as chairman.
Reported
Fosun Pharma and Sinopharm sign vaccine logistics partnership[15]
Fosun Pharma and Sinopharm Holding signed a strategic logistics cooperation agreement for the BioNTech mRNA vaccine, including plans to jointly establish a vaccine cold-chain system and improve storage, transport and distribution services.
Reported
Fosun Pharma and Polyphor sign Balixafortide license agreement[16]
Fosun Pharma and Polyphor announced an exclusive license agreement for Balixafortide in mainland China, Hong Kong, and Macau and Taiwan. Fosun Pharma’s subsidiary is authorized to clinically develop and commercialize the drug in the territory.
- Unconfirmed
Hong Kong Stock Exchange approves Gland Pharma overseas listing proposal[17]
Fosun Pharma announced that the Hong Kong Stock Exchange had approved the proposed overseas listing of Gland Pharma. The article says the listing still required, among other things, approval from relevant Indian regulators and was not guaranteed to proceed.
Reported
Pfizer responds to controversy over China’s exclusion from vaccine collaboration[9]
Pfizer said its collaboration with BioNTech did not include China because BioNTech had already partnered with Fosun Pharma for the Chinese market. Pfizer said it was working to resolve details and was committed to access to medicines and vaccines for patients in China and globally.
- Unconfirmed
ACCA and Fosun Pharma sign strategic cooperation memorandum[18]
ACCA and Fosun Pharma signed a strategic cooperation memorandum covering finance-management transformation, finance talent development, and support for Fosun Pharma's global development.
Sources20 sources
- 1Fosun Pharma - Wikipediaen.wikipedia.org
- 2Fosun Pharma official websitefosunpharma.com
- 3关于复星医药-复星医药fosunpharma.com
- 4公司简介_复星医药介绍-复星医药fosunpharma.com
- 5品牌文化_关于复星医药-复星医药fosunpharma.com
- 6Subsidiary Has Drug GMP Certificate Revoked for Violationsce.cn
- 7Ministry of Finance's Major Pharma Audit: Subsidiary Fined Over Promotion Fee Invoicesjiemian.com
- 8Ministry of Finance's Major Pharma Audit: Subsidiary Fined Over Promotion Fee Invoicesfinance.ifeng.com
- 9Pfizer responds to controversy over China’s exclusion from vaccine collaborationfinance.sina.com.cn
- 10La Jolla Pharmaceutical sues over Giapreza patentslawstreetmedia.com
- 11BioNTech vaccine batch paused in Hong Kong and Macau after vial-cap defectnbd.com.cn
- 12复星医药与英矽智能宣布人工智能药物研发战略合作news.cnfol.com
- 13复星实业签订台湾地区疫苗销售协议finance.sina.com.cn
- 14复星医药任命吴以芳为董事长兼首席执行官finance.sina.com.cn
- 15复星医药与国药控股签署疫苗物流合作协议finance.sina.com.cn
- 16复星医药与Polyphor签订Balixafortide许可协议finance.sina.com.cn
- 17香港联交所批准Gland Pharma境外上市事项finance.qianlong.com
- 18ACCA与复星医药签署战略合作备忘录hy.stock.cnfol.com
- 19复星医药荣获2019中国医药上市公司竞争力系列榜单双项大奖finance.sina.com.cn
- 20独家丨复星医药与国药控股签署关于BioNTech mRNA新冠疫苗物流合作协议finance.sina.com.cn
Cite this profile: Cite the canonical profile. /brand-wiki/fosun-pharma · Editorial policy · How profiles are compiled